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Objectives:
 
 The objective of this study was to develop a
model capable of assessing the cost-effectiveness in Swe-
den of treating diabetic neuropathic lower extremity ul-
cers with becaplermin gel (Regranex) plus good wound
care (GWC) relative to treating them with GWC alone.
 
Methods:
 
 A Markov simulation model was developed
that includes six health states: Uninfected Ulcer, Infected
Ulcer, Gangrene, Healed Ulcer, Healed Ulcer-History of
Amputation, and Deceased. To predict clinical outcomes,
information was taken from a specially designed pro-
spective 9-month follow-up study of 183 neuropathic pa-
tients in the US treated with GWC. Cost of treatment
data were taken primarily from a study of a cohort of
314 patients in Sweden. The efficacy of becaplermin was
assumed equal to that achieved in a pooled analysis of
four randomized clinical trials. A model application pro-
vides expected clinical outcomes for a cohort of patients.
Annual treatment costs per patient were estimated using
treatment practice and unit prices from Sweden.
 
Results:
 
 Due to a higher rate of healing and a shorter
average healing time, treatment with becaplermin gel
was predicted to increase the average number of months
spent in the healed state over the first year following
development of an ulcer by 24% relative to GWC
alone. In addition, the corresponding number of ampu-
tations was 9% lower for the becaplermin-treated cohort.
The average expected cost of $12,078 US for an indi-
vidual treated with GWC alone declines to $11,708 US
for one treated with becaplermin, in spite of $1262
becaplermin costs. Expenses related to topical treat-
ment and inpatient care account for 83% of the re-
sources conserved.
 
Conclusions:
 
 Our results suggest that in Sweden treat-
ment with becaplermin in conjunction with GWC con-
sumes fewer resources and generates better outcomes
than treatment with GWC alone for diabetic neuropathic
ulcers. In light of the high and increasing incidence of
such ulcers, the potential savings in costs and suffering
may be important. Results are difficult to extrapolate in-
ternationally because they are strongly related to coun-
try-specific treatment practices and price levels.
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Introduction
 
Lower extremity ulceration is a common but seri-
ous complication of diabetes Mellitus (DM), often
resulting in chronic nonhealing wounds that leave
sufferers vulnerable to infection, gangrene and ul-
timately to amputation. In fact, it has been singled
out as one of the most common and costly of the
diabetic complications [1,2]. Every year, between
2.2 and 5.9% of DM patients in industrialized na-
tions develop a lower extremity ulcer [3].
Recent studies illustrate the economic burden of
lower extremity ulcers. In the US, for example, it
was estimated that $150 million was spent treating
NIDDM patients for chronic skin ulcers, a subset
of all lower extremity ulcers, and this did not even
include costs for amputations [4]. At a disaggregate
level, Medicare reimbursement for inpatient treat-
ment of skin ulcers (DRG 271) was $4862 in 1995,
reflecting an 8.8-day length of hospital stay [5]. Pri-
vate insurance reimbursed almost twice as much,
some $8,988, in part the consequence of almost
three additional inpatient days [5]. In Sweden, it
has been estimated that the average direct cost for
patients who heal primarily are $8500 [6]. The cor-
responding costs for patients requiring minor am-
putation and major amputation are $43,000 and
$65,000, respectively [6]. Current treatment of neu-
ropathic ulcers is multidisciplinary [6,7]. In centers
of excellence, treatment is successful and heals 80
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and 90% of the ulcers [3]. In other settings, the
healing rate is often lower.
Becaplermin gel (Regranex), a novel biotech-
nology product containing recombinant human
platelet derived growth factor (rhPDGF-BB), has
been shown to stimulate the healing process in is-
chemia-free, neuropathic ulcers when combined
with good wound care (GWC) practices.
The objective of this study was to develop a
model capable of assessing the cost-effectiveness
in Sweden of treating diabetic neuropathic lower
extremity ulcers with becaplermin gel plus GWC
relative to treating them with GWC alone.
 
Methods
 
Computer simulation techniques can be used to
combine data from different sources into a cohe-
sive epidemiological model [8]. The Markov ap-
proach is well suited to modeling decision prob-
lems that involve probabilities of transition among
discrete states for which timing is important [9].
For diabetic lower extremity ulcers, a sequence of
well-defined health states exists and transition be-
tween them is easily measurable.
As part of a recent cost of illness study, Abt As-
sociates, Inc. (Abt Inc., Cambridge, MA) developed
a Markov model of diabetic neuropathic lower ex-
tremity ulcers [10]. At any point in time, model
subjects are considered to be in one of five health
states: Uninfected, Infected, Healed, Amputated,
or Deceased. Based on a US sample of 194 IDDM
and NIDDM patients, rates of transition between
the various health states were estimated. Several
important features of the pathology of lower ex-
tremity ulcers are overlooked in this model, how-
ever. For instance, gangrene, which can be a costly
outcome of chronic ulcers and usually results in
amputation, is not included. Moreover, the model
treats amputation as an endpoint, even though
amputees incur long-term costs related to reduced
mobility and are at risk for re-amputation.
Starting with the Abt model, a more complete
model of lower extremity ulcers for cost-effective-
ness analysis was developed. It includes Gangrene
as a separate health state and it models postampu-
tation pathology explicitly. An important concep-
tual difference is that Amputated is no longer con-
sidered a health state, but is modeled instead as a
treatment that may promote healing.
 
The Core Simulation Model
 
Our model of lower extremity ulcers includes six
health states: Uninfected (Deep) Ulcer, Infected
(Deep) Ulcer, Gangrene, Healed Ulcer, Healed Ul-
cer-History of Amputation, and Deceased (Fig. 1).
The first three health states correspond to Wagner
grades 2, 3, and 4, respectively [11]. Superficial ul-
cers (Wagner grade 1) are not included. Initially,
each member of a cohort of DM patients has an
uninfected ulcer. Over the course of the first
month, uninfected ulcers can either heal, remain
the same, or become infected, or the patient can
die. The transitions are governed by transition
probabilities. Those that remain in the Uninfected
Ulcer health state face similar risks the next time
period. The cohort is followed on a monthly basis
for one year.
Patients with infected ulcers may remain the
same, experience successful healing of the underly-
ing infection (return to Uninfected Ulcer), undergo
a successful or an unsuccessful amputation, de-
velop gangrene or die. It should be noted that suc-
cessful primary healing of an infected ulcer re-
quires two steps. First, successful healing of the
infection must be achieved. In subsequent months,
successful healing of the uninfected ulcer can be
achieved.
Patients with gangrene may undergo amputa-
tion, they may die, or they may remain in Gan-
grene. Amputation can lead either to successful
healing or to continued gangrene with a subse-
quent exposure to re-amputation.
Figure 1 Diabetic foot ulcer transition diagram.
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Patients who heal primarily, that is, who transit
to Healed Ulcer from Uninfected Ulcer, face a risk
of dying and a risk of ulcer recurrence. The latter
is modeled as a transition back to Uninfected Ul-
cer. To simplify the model and increase its trans-
parency, patients who achieve healing with ampu-
tation face no risk of ulcer recurrence. That is, the
only transition out of Healed Ulcer-History of
Amputation is to Deceased. A comparison of re-
sults suggests that this assumption is minor. Fi-
nally, Deceased is an absorbing state.
 
Epidemiological Data
 
Monthly probabilities for the transition between
the various health states are presented in Table 1.
The transition probabilities that were estimated by
Abt formed the starting point because the patients
in that study were recruited to assess the cost of
deep, ischemia-free, diabetic neuropathic lower
extremity ulcers, exactly the type of wounds for
which becaplermin is indicated.
The Abt model and the one presented here do
not coincide exactly; several assumptions and ad-
ditional estimates were necessary.
The proportion of amputations that are suc-
cessful is used to subdivide the Abt probability
that an Infected Ulcer is amputated into the prob-
abilities of successful healing and failure (i.e., re-
maining in Infected Ulcer).
The direct transition from Uninfected Ulcer to
Gangrene was disallowed.
The monthly probability that Gangrene is am-
putated was estimated to be 49% (calculations
based on data described in [6]) and, as with In-
fected Ulcer, it is subdivided between successful
healing (31%) and failure (i.e., remaining in Gan-
grene) (18%).
The probability of transition between Infected
Ulcer and Gangrene was calibrated using an as-
sumption that infected ulcers are the cause of
about 80–85% of ulcer-related amputations and
gangrene is the cause of the remaining 15–20%. A
monthly transition probability of 0.75% achieves
this balance.
Mortality risks, also based on Abt data, are
0.40% per month (4.7% per year) for Healed Ul-
cer and Uninfected Ulcer and 0.98% per month
(11.1% per year) for Infected Ulcer and Gangrene.
Conservatively, it was assumed that gangrene has
the same mortality risk as Infected Ulcer. That is,
no incremental mortality risk for amputation is
modeled. Based on the outcomes of 274 Swedish
patients, it was assumed that 92% of amputations
are successful for patients with infected ulcers and
63% are successful for patients with gangrene
(calculations based on data described in [6]).
 
Cost Estimates
 
Long-term follow-up data on resource utilization
in Sweden were taken from a series of studies in
Sweden [6,7,12,13]. Only direct costs are included
and presented in 1999 US dollars. Monthly cost
estimates for each of the various health states and
amputation are shown in Table 2.
The cost of topical treatments (not including
becaplermin) was taken from [12] where the cate-
gories Deep Ulcer, Abscess, and Gangrene match
our categories Uninfected Ulcer, Infected Ulcer, and
Gangrene. Specifically, resource intensity weights
were combined with weekly costs for each of the
categories, and then the costs were converted from
1990 Swedish kronor (SEK) to 1999 dollars per
month. The cost of antibiotics was taken directly
from Appendix 1 in [6], though it was allocated
only to Infected Ulcer. The cost of outpatient care
for Uninfected Ulcer was assumed to include one
physician visit and one test battery per month [6].
Two physician visits were assigned for Infected Ul-
cer and Gangrene.
The average costs for episodes of superficial,
uninfected, infected, and gangrenous ulcers were
taken from [6]. We arrived at average monthly
costs by dividing these episodic costs by average
healing times of three months for superficial ul-
cers, six months for uninfected and infected ulcers,
 
Table 1
 
Monthly probabilities for lower extremity ulcer 
transitions (%)
 
Transition Probability (%)
Uninfected Ulcer
 
→
 
Healed Ulcer 7.87*
Uninfected Ulcer
 
→
 
Infected Ulcer 4.73*
Infected Ulcer
 
→
 
Uninfected Ulcer 13.97*
Infected Ulcer
 
→
 
Gangrene 0.75
 
†
 
Infected Ulcer
 
→
 
Amputation Healed Ulcer, 
History of Amputation 4.45
 
‡
 
Infected Ulcer
 
→
 
Amputation
 
→
 
Infected Ulcer 0.37
 
‡
 
Gangrene
 
→
 
Amputation
 
→
 
Healed, History of 
Amputation 30.82
 
§
 
Gangrene
 
→
 
Amputation
 
→
 
Gangrene 18.18
 
§
 
Healed Ulcer
 
→
 
Uninfected Ulcer 3.93*
Healed Ulcer
 
→
 
Deceased 0.40*
Uninfected Ulcer
 
→
 
Deceased 0.40*
Infected Ulcer
 
→
 
Deceased 0.98*
Gangrene
 
→
 
Deceased 0.98*
Healed Ulcer, History of Amputation 
 
→
 
Deceased 0.40*
 
*Abt data [10]. 
 
†
 
Calibrated to match observed amputation patterns (see text).
 
‡
 
The probability of amputation is drawn from Abt data [10]. The proportion of
successful and unsuccessful procedures is drawn from Apelqvist et al data
[12,13]. 
 
§
 
The probability of amputation was estimated using Apelqvist et al data
[12,13], as was the proportion of successful and unsuccessful procedures.
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and seven months for gangrenous ulcers [7]. Inpa-
tient care costs that were attributable to the foot
ulcer were estimated by calculating the difference
between the cost of each ulcer type and that of su-
perficial ulcers. The cost of orthopedic appliances
was estimated using a price list for custom-made
treatment shoes, individually fitted insoles, hand-
made orthopedic shoes, and walking casts [6], and
ulcer-specific data on average yearly consumption.
We estimate the average cost of an amputation
procedure in Sweden (not including follow-up costs)
as a weighted average of the costs of DRG 114
(minor amputation) and DRG 285 (major amputa-
tion) plus a weighted average of the costs of pros-
theses [13]. According to official Swedish sources
[14], DRG 114 is reimbursed at $2928 (SEK
25,485) and DRG 285 is reimbursed at $8719
(SEK 75,900). Average prosthesis costs have been
estimated at $1211 and $2126 for minor and major
amputations, respectively [6].
Lower extremity ulcers are associated with an in-
creased dependence on social services and home care,
particularly following amputation [6]. A monthly
cost for the postamputation health state was cal-
culated as a weighted average of the costs for mi-
nor and major amputation. The monthly costs for
primarily healed patients are assumed to be zero.
 
Intervention
 
We model becaplermin treatment as administered
for an initially Uninfected Ulcer according to Eu-
ropean guidelines. Treatment is continued until
the first of the following markers is reached: heal-
ing occurs, the ulcer progresses, the patient dies,
or a five-month time limit expires. Only one epi-
sode of treatment is approved for use in Europe,
so ulcer recurrences are treated only with GWC.
A series of randomized clinical trials (RCTs)
compared becaplermin gel plus GWC vs. GWC
alone. In the analysis that pooled the results of all
the RCTs covering more than 500 patients, the
20-week healing rate was 35% for GWC alone
and 47% for GWC in combination with becapler-
min gel. The detailed bi-weekly data available
from the largest of the RCTs, Regranex Study 2
(the K-Trial), enables estimation of the monthly
healing probabilities [15]. An exponential survi-
vor curve was seen to provide a good fit, giving
rise to time-invariant monthly healing probabili-
ties of 13.5% for becaplermin and 9.0% for GWC
alone. Therefore, becaplermin improved the esti-
mated monthly healing probability of GWC alone
by 50%. Because the K-trial and the pooled trials
had virtually the same healing rates, we model be-
caplermin treatment as a 50% improvement in the
Abt 7.87% monthly probability of healing.
In Sweden, one tube of becaplermin gel is ex-
pected to cost the pharmacy about $418. After
adding the appropriate mark-ups, the price will
rise to about $445. It has been assumed that a
tube lasts 5 weeks. The effective monthly price is
thus $356.
The recommended becaplermin protocol in Swe-
den consists of dry saline gauze dressings changed
once daily by a nurse. Savings in nursing resources
are not modeled here. Savings in materials are easier
to document and hence are modeled here. The
monthly cost of once daily dry saline gauze is
$132 less than the average dressing cost estimated
for Uninfected Ulcer by Apelqvist et al. [12]. This
reduces the effective cost of becaplermin by the
same amount.
 
Outcomes
 
Becaplermin can benefit patients both by increas-
ing the fraction of ulcers that heal primarily and,
in those that do heal, by shortening the average
healing time. As a consequence, reductions in epi-
sodes of infection, gangrene, and amputation, will
translate into long-run resource savings and im-
proved quality of life. Our primary outcome mea-
sure is the cost per ulcer-day averted.
 
Table 2
 
Treatment costs for lower extremity ulcers in Sweden (1999 $US)
 
Treatment (monthly unless
otherwise indicated)
Healed
Ulcer
Uninfected
Ulcer
Infected 
Ulcer Gangrene
Healed Ulcer-History
of Amputation Amputation
Topical Treatment [12] 0 677 718 689 0 0
Antibiotics [7] 0 0 80 0 0 0
Other Outpatient Care [7] 0 117 188 188 0 0
Inpatient Care [7] 0 540 540 1,440 0 0
Orthopedic Appliances [7] 0 33 45 32 0 0
Social Services/Home Care [7] 0 0 0 0 779 0
Amputation (per procedure) [13,14] 0 0 0 0 0 6,789
Prosthesis (per amputation procedure) [13,14] 0 0 0 0 1,821
Total 0 1,367 1,572 2,349 779 8,610
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Discounting
 
Costs are discounted at 0.42% per month (5% per
year), which is consistent with widely followed
guidelines in Europe [16]. Drummond et al. [16]
provide arguments both in favor of and against
discounting the benefits, and it is often good prac-
tice to present both sets of results. In our case,
however, the short one-year time frame ensures
that both sets of results are nearly identical and
our finding of cost savings makes a direct compar-
ison of costs and benefits unnecessary. We present
only undiscounted benefit measures because they
provide a better representation of the actual bene-
fits of therapy, for example, the number of ulcer-
months and amputations that can be avoided.
 
Sensitivity to Model Assumptions
 
In order to test the sensitivity of the results to
some of our key assumptions, the following pa-
rameters were varied:
(i) The relative improvement in monthly healing
rates (efficacy) attributable to becaplermin
(minimum 24%, maximum 76%);
(ii) Baseline monthly healing rate for GWC alone
(9%);
(iii) Longer time frame (18 and 24 months);
(iv) No short-run conservation of topical treat-
ment resources; and
(v) Number of weeks that a tube of becaplermin
lasts (minimum 4 weeks, maximum 6 weeks).
The minimum and maximum values of the rela-
tive improvement in monthly healing rates (effi-
cacy) in sensitivity test (i) were chosen to corre-
spond with the individual RCTs that had the
lowest and highest 20-week healing rates, respec-
tively. More specifically, when compared to the
baseline 35% 20-week healing rate for GWC
alone, the 42% healing rate for becaplermin ob-
served in the least successful RCT translates into a
24% relative improvement in the monthly healing
rate. Similarly, the healing rate with becaplermin
in the most successful RCT, 52% over 20 weeks,
translates into a 76% improvement in the monthly
healing rate. The 9% monthly healing rate for
GWC alone in sensitivity test (ii) is based on the
results of the placebo arm of the RCTs [15]. The
duration of a tube will vary in actual practice, so
the model is also simulated in sensitivity test (v)
using durations of 4 weeks and 6 weeks.
 
Results
 
In the cohort simulated with only GWC, 30.4% of
the patients healed from the initial ulcer within the
first five months. In the becaplermin-treated cohort,
42.1% healed from the initial ulcer during the
five-month treatment phase. Though only minor
gains in life expectancy were seen over the course
of the year, the increase in the healing rate trans-
lates directly into more months free of ulcers and
fewer months spent suffering from them (Table 3).
The average number of months spent in the healed
state rose from 3.41 to 4.22, an increase of 24%.
The number of amputations declined by 9%.
These sizable health gains translate into cost-
savings over 12 months (Table 3). The expected
cost of $12,078 for an individual treated with
 
Table 3
 
The benefits and costs of becaplermin over a 12-month time horizon
 
Good wound
care alone Becaplermin Difference
Benefits:
Months in Healed State 3.41 4.22 0.81
Months with Ulcers 8.30 7.49 0.81
Amputations (per 100 individuals) 6.50 5.91 0.59
Costs (1999 $US):
Recurring Costs:
• Topical Treatment 5,560 4,550 1,009
• Antibiotics 90 82 8
• Other Outpatient 1,032 932 100
• Inpatient 4,414 3,985 429
• Orthopedic Appliances 285 257 28
• Social Service/Home Care 189 176 13
Sub-Total 11,570 9,983 1,587
One-time Costs:
• Amputation 401 365
 

 
36
• Prostheses 108 98
 

 
10
Sub-Total 508 463
 

 
46
Becaplermin 0 1,262
 

 
1,262
Grand Total 12,078 11,708
 

 
370
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GWC alone declines to $11,708 for an individual
treated with becaplermin, in spite of $1262 beca-
plermin costs. Topical treatment (not including
becaplermin) and inpatient care account for 83%
of the resources conserved. Fully $1009 can be
saved in topical treatment expenses and $429 in
inpatient care can be avoided. The savings in anti-
biotics, physician visits, orthopedic appliances, so-
cial services/home care, amputations, and prosthe-
ses are modest.
 
Sensitivity Analysis
 
The sensitivity analysis suggests our estimates are
relatively insensitive to changes in most key pa-
rameters. Table 4 shows the following results of
varying five key assumptions, one at a time. In
Panel A, it can be seen that becaplermin is not cost
saving at only a 24% improvement in monthly
healing rates (42% 20-week RCT healing rate).
The break-even point occurs at about 34% im-
provement in healing (43% 20-week RCT healing
rate). The cost savings are $942 when the im-
provement in efficacy is 76%.
 
Discussion
 
This is the first comprehensive model developed
that is suitable for cost-effectiveness analyses of
diabetic foot ulcer treatments. Clinical and eco-
nomic outcomes are predicted using data from a
specially designed follow-up study of 183 neuro-
pathic ulcer patients treated with usual GWC in
the US. The model is applied to Sweden using
published cost of treatment data from a study of
the treatment patterns and unit costs of 314 pa-
tients in the south of Sweden, the only such study
available.
Using efficacy data from a pooled analysis of
four RCTs of becaplermin gel to model the im-
provement over GWC, an economic evaluation of
GWC plus becaplermin vs. GWC alone in Sweden
was conducted. The results suggest that treating
neuropathic lower extremity foot ulcers with be-
caplermin treatment plus GWC is less expensive
than treating them with GWC alone in Sweden,
and this holds true even when various model pa-
rameters are altered. The principal explanation is
that a greater fraction of ulcers healed, and those
that did so healed faster on average, thus reducing
the number of patient-months that require costly
treatment.
The model relies heavily on data compiled by
Abt so several features of the data may influence
the results. First, only 194 patients were recruited,
so the transition probability estimates may be im-
precise. Second, the transition probabilities may
not be applicable to cohorts of all ages. Rather,
our results may apply best to cohorts similar in
age to the Abt sample, where the median patient
age was 60 years and 60% of the sample was be-
tween the ages of 51 and 70. Care must be used in
extrapolating results to a group of either very
young or very old patients. Third, the sample
members were drawn from the US and not the
Swedish population.
Nevertheless, two important strengths of the
Abt data act to offset these shortcomings. The
sample inclusion criteria correspond exactly to pa-
 
Table 4
 
Sensitivity of the results to alternative assumptions (1999 US$)
 
Good wound 
care alone Becaplermin Difference
Improvement in Efficacy:
24% (i.e., 42% 20-Weeks Healing Rate) 12,078 12,324 246
50% (i.e., 47% 20-Weeks Healing Rate) 12,078 11,708
 

 
370
76% (i.e., 52% 20-Weeks Healing Rate) 12,078 11,136
 

 
942
Good Wound Care Healing Rate:
7.87% per Month 12,078 11,708
 

 
370
9.00% per Month 11,597 11,120
 

 
477
Time Horizon:
12 Months 12,078 11,708
 

 
370
18 Months 16,034 15,348
 

 
686
24 Months 19,370 18,521
 

 
849
Becaplermin Treatment Protocol:
Savings in Topical Treatment Costs 12,078 11,708
 

 
370
Equivalent Topical Treatment Costs 12,078 12,176 98
Duration of 1 Becaplermin Tube
4 Weeks per Tube 12,078 12,023
 

 
55
5 Weeks per Tube 12,078 11,708
 

 
371
6 Weeks per Tube 12,078 11,498
 

 
580
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tients that are eligible for treatment with becapler-
min and the transition probabilities were estimated
using an epidemiological model very similar to
ours. It should also be noted that the Abt healing
rate of 7.87% per month, used in this application,
is lower than the implied monthly healing rate of
9% found in the becaplermin RCTs. In a RCT for
another product in the UK, the implied monthly
healing rate for GWC alone was of the same mag-
nitude; 13% when calculated over only the first 12
weeks and 7% when calculated over 32 weeks
[17]. RCTs typically have higher healing rates than
seen in normal treatment settings, however, so this
application is based on conservative assumptions
about the baseline efficacy.
The reduction in the incidence of gangrene and
amputation suggests there may be important life
quality differences between patients treated with
becaplermin plus GWC and patients treated with
GWC alone. Because no satisfactory life quality
weights were available, however, the model results
do not include this human dimension and hence
are likely to be conservative.
Our model was also run for 18 and 24 months
(see Table 4). As becaplermin treatment is not in-
dicated for ulcer recurrences in Europe, it has no
direct effect during these additional months. How-
ever, the costs of treating complications and post-
amputation follow-up continue to accumulate so
the healthier distribution of patients in the becap-
lermin-treated cohort continues to generate cost
savings. Moreover, with a longer time frame, the
model is more sensitive to changes in the inci-
dences of gangrene and amputations, though ex-
trapolation of results over this longer time frame
also increases modeling uncertainty.
Though the epidemiological data in the model
were taken primarily from US Abt study data, the
economic analysis has been customized to condi-
tions seen in Sweden. In particular, monthly treat-
ment costs are based on treatment patterns, re-
source usage and unit costs as practiced in south
Sweden. It may be that the economic data reflect
above-average resource consumption, thus, and
that the actual cost-effectiveness may be lower in
less resource-intensive settings. Moreover, reim-
bursement systems, relative prices, and treatment
patterns may have important impacts on resource
usage and costs, so even if becaplermin was associ-
ated with cost savings in Sweden under a variety of
assumptions, it is tenuous to extrapolate these re-
sults to countries with different health care systems.
Becaplermin is not approved for superficial ul-
cers and ischemia and the cost-effectiveness of
treating patients with such ulcers is not estab-
lished. The model can be modified to analyze
other types of diabetic foot ulcer, however. Eco-
nomic evaluations can also be undertaken in a
way that facilitates analyzing more than one coun-
try with the same, or nearly the same, model.
 
Conclusion
 
Model results presented here suggest that, for dia-
betic neuropathic ulcers in Sweden, becaplermin
treatment in conjunction with GWC consumes
fewer resources and generates better outcomes
than does GWC alone. In light of the high and in-
creasing incidence of such ulcers, the potential
savings in costs and suffering may be important.
Results are difficult to extrapolate internationally
because they are strongly related to treatment
practices and price levels in different countries.
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